Found 53 administration trials
A listing of administration medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Our pilot study will evaluate whether the activation of antiviral innate mechanisms by administration of Pegylated Interferon alpha 2b (peg-IFN-2b) when combined with two broadly neutralizing antibodies (3BNC117 and 10-1074) in HIV positive participants with well controlled viral replication can result in viral control in the absence of ART or …
Randomized, single blinded crossover trial testing optimal interventions to adequately suppress myocardial glucose suppression. We will enroll up to 50 subjects in order to reach our target of 40 fully evaluable; 20 healthy volunteers and 20 patients with Type 2 diabetes mellitus. We will test whether dietary modification (ketogenic diet) …
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …
Cognition Therapeutics is developing an oral formulation of CT1812 to treat AD and mild cognitive impairment. This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD, sponsored by the NIH. The primary purpose of this study is to evaluate target engagement of …
Traumatic cerebrovascular injury (TCVI) is common after traumatic brain injury (TBI) and an attractive target for therapeutic intervention. We will longitudinally measure cerebrovascular reactivity (CVR) by functional near-infrared spectroscopy (fNIRS) in acute (3 days from injury), subacute, and chronic phases after TBI as a biomarker of TCVI as compared to …
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the treatment of pain and inflammation. Mounting evidence indicates that rectal administration of NSAIDs is also effective in preventing pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP) by an unknown mechanism. Alterations in the salivary and fecal microbiome have been observed in patients with …
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced -cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions …
The Exablate Model 4000 Type-1.0/1.1 Neuro system involves using an advanced, non-invasive technique currently approved by the Food and Drug Administration (FDA) to treat one side of your brain in a procedure called a thalamotomy (lesion the thalamus). This procedure involves performing an ablation (lesion) of an area of the …
The purpose of this study is to determine how psoriatic nail disease is affected by secukinumab. Secukinumab (Cosentyx®) is a prescription medicine that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis in adults. While …
